0 559

Cited 23 times in

Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)

DC Field Value Language
dc.contributor.author이용재-
dc.contributor.author이정윤-
dc.date.accessioned2019-12-18T01:12:19Z-
dc.date.available2019-12-18T01:12:19Z-
dc.date.issued2019-
dc.identifier.issn0090-8258-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173415-
dc.description.abstractPURPOSE: To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. PATIENTS AND METHODS: We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan) between 2015 and 2017 for second- or third-line chemotherapy in routine clinical practice. The primary endpoint was progression-free survival (PFS) and safety. Secondary endpoints included the objective response rate (ORR), PFS2, overall survival, duration of chemotherapy, and reasons for discontinuing chemotherapy. RESULTS: Of 391 patients, 259 (66.2%) received bevacizumab with PLD, 94 (24.0%) with topotecan, and 38 (9.7%) with weekly paclitaxel. The median PFS was 6.1 months with all forms of bevacizumab-containing therapy. Although the cohort with weekly paclitaxel had a better PFS than the PLD cohort (P = 0.028), this finding was not found in patients with a previous platinum-free interval of less than three months. The median duration of therapy was five cycles (range, one to 20 cycles), and 29 patients (7.4%) discontinued treatment because of adverse events from bevacizumab-containing regimens. The PLD cohort had fewer grade ≥ 3 adverse events than the other regimens (PLD, 35.8%; weekly paclitaxel, 52.6%; topotecan, 51.1%; P = 0.012), especially events of hematologic toxicities. CONCLUSION: In Korean ovarian cancer patients, the safety and effectiveness of chemotherapy with bevacizumab in a real-world setting was consistent with the results from a randomized controlled study. The effectiveness and toxicity profiles varied among the chemotherapy regimens, and this finding should be considered in practice. CLINICAL TRIALS REGISTRATION: NCT03367182.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherAcademic Press-
dc.relation.isPartOfGYNECOLOGIC ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHBevacizumab/administration & dosage-
dc.subject.MESHDoxorubicin/administration & dosage-
dc.subject.MESHDoxorubicin/analogs & derivatives-
dc.subject.MESHDrug Resistance, Neoplasm-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local/drug therapy*-
dc.subject.MESHNeoplasm Recurrence, Local/mortality-
dc.subject.MESHOvarian Neoplasms/drug therapy*-
dc.subject.MESHOvarian Neoplasms/mortality-
dc.subject.MESHPaclitaxel/administration & dosage-
dc.subject.MESHPlatinum/therapeutic use-
dc.subject.MESHPolyethylene Glycols/administration & dosage-
dc.subject.MESHTopotecan/administration & dosage-
dc.titleReal-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Obstetrics and Gynecology (산부인과학교실)-
dc.contributor.googleauthorJung-Yun Lee-
dc.contributor.googleauthorJeong-Yeol Park-
dc.contributor.googleauthorSang Yoon Park-
dc.contributor.googleauthorJeong-Won Lee-
dc.contributor.googleauthorJae Weon Kim-
dc.contributor.googleauthorYong Beom Kim-
dc.contributor.googleauthorDae Hoon Jeong-
dc.contributor.googleauthorKwang-Beom Lee-
dc.contributor.googleauthorTae-Hun Kim-
dc.contributor.googleauthorIn Ho Lee-
dc.contributor.googleauthorMin Chul Choi-
dc.contributor.googleauthorKi Hyung Kim-
dc.contributor.googleauthorYong-Man Kim-
dc.contributor.googleauthorYong Jae Lee-
dc.contributor.googleauthorSokbom Kang-
dc.contributor.googleauthorKGOG Investigators-
dc.contributor.googleauthorEric Pujade-Lauraine-
dc.identifier.doi10.1016/j.ygyno.2018.10.031-
dc.contributor.localIdA05165-
dc.contributor.localIdA04638-
dc.relation.journalcodeJ00956-
dc.identifier.eissn1095-6859-
dc.identifier.pmid30409490-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0090825818313143-
dc.subject.keywordBevacizumab-
dc.subject.keywordChemotherapy-
dc.subject.keywordOvarian cancer-
dc.subject.keywordPlatinum-resistant-
dc.subject.keywordReal world-
dc.contributor.alternativeNameLee, Yong Jae-
dc.contributor.affiliatedAuthor이용재-
dc.contributor.affiliatedAuthor이정윤-
dc.citation.volume152-
dc.citation.number1-
dc.citation.startPage61-
dc.citation.endPage67-
dc.identifier.bibliographicCitationGYNECOLOGIC ONCOLOGY, Vol.152(1) : 61-67, 2019-
dc.identifier.rimsid64367-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.